Abstract 3965
Background
Olaparib (Lynparza®) is a poly(ADP-ribose) polymerase (PARP) inhibitor that prevents the repair of single-strand DNA breaks. Durvalumab (Imfinzi®) is a programmed cell death ligand 1 (anti-PD-L1) inhibitor, which functions by promoting antitumour immune responses. Inhibition of vascular endothelial growth factor (VEGF) has been reported to enhance PARP inhibitor activity. Combinations of immune checkpoint inhibitors and bevacizumab have shown promising results in other tumour types. Here, the efficacy and safety of bevacizumab (anti-VEGF-A antibody) is investigated in combination with olaparib + durvalumab in platinum-sensitive relapsed (PSR) non-gBRCAm ovarian cancer (OC) pts (NCT02734004).
Trial design
Initially, 148 pts were enrolled across several tumour types (small-cell lung cancer, gastric cancer, germline BRCA-mutated [gBRCAm] breast cancer, or PSR gBRCAm OC). Pts received olaparib 300 mg po bid for a 4-wk run-in, followed by olaparib 300 mg po bid and durvalumab 1.5 g IV q4w. Primary endpoints were disease control rate (DCR) at 12 wks, safety and tolerability. Secondary endpoints: pharmacokinetics (PK), DCR at 28 wks, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Tumours were assessed at baseline, 4 wks and every 8 wks thereafter. Enrolment was completed for these initial cohorts, and new PSR OC cohorts (Table) have been added, based on the preliminary results. These cohorts have no olaparib run-in, tumour assessments are performed at baseline and every 8 wks thereafter, bevacizumab 10 mg/kg is given q 2 weeks, and pts with 1–2 prior chemotherapy lines are allowed.Table: 448TiP
New MEDIOLA cohorts
| OC cohort name | Drugs | Population | Primary endpoint |
|---|---|---|---|
| Expansion (N = 80) | Olaparib+Durvalumab | gBRCAm | ORR |
| Doublet (N = 30) | Olaparib+Durvalumab | non-gBRCAm | DCR 24 wks |
| Triplet (N = 30) | Olaparib+Durvalumab+ Bevacizumab | non-gBRCAm | DCR 24 wks |
Other endpoints: Safety and tolerability, PK, DCR at 56 wks, ORR, PFS, and OS. Biomarker endpoints: Analysis of tumour-infiltrating lymphocytes and PD-L1 expression.
Clinical trial identification
NCT02734004.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Editorial Acknowledgement
n/a
Disclosure
R.T. Penson: Scientific advisory boards: Amgen Inc., Genentech, Inc., AstraZeneca, Endocyte Inc., Eisai Inc., Vascular Biogenics Ltd, Baxalta Oncology, AbbVie, Clovis Oncology, Tesaro; Research funding: Genentech Inc., ImClone Systems Inc., Endocyte Inc., AstraZeneca, Eisai Inc., Amgen Inc., Vascular Biogenics Ltd; Royalties: BMJ, Blackwell; Publishing Medicine at a Glance, UpToDate Commercial: Advance Medical: Second Medical Opinion. B. Kaufman: Advisory board: AstraZeneca. C. Gresty, H.K. Angell, K. Meyer, M. Lanasa, P. Herbolsheimer: Employee and stockholder: AstraZeneca. S. Domchek: Honoraria: AstraZeneca, Clovis, and Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract